| Meta-analysis summary statistics for associations meeting genome-wide significance | |||||||
|---|---|---|---|---|---|---|---|
| Lead SNP | Biochemicals | EA/OA | Ntotal | EAF | Effect (SE) | Pmeta | Details |
| rs6980334 | X-12095--N1-methyl-3-pyridone-4-carboxamide / X-12844 | A/G | 7220 | 0.76 | -0.038 (0.004) | 4.48·10-20 | show |
| rs2035647 | X-12844 | A/G | 7322 | 0.21 | -0.029 (0.003) | 2.18·10-17 | show |
EA = effect allele; OA = other allele; EAF = frequency of effect allele;
| Summary of biological annotations | |
|---|---|
| SNP | rs6980334 |
| Chromosomal location | Chr7: 137,439,032 (7q34) |
| Gene (distance) | AKR1D1 (0) |
| Predicted causal gene | AKR1D1 |
| Gene/protein classification | metabolic enzyme |
| Metabolite (Pathway) | X-12095--N1-methyl-3-pyridone-4-carboxamide (NAD metabolism; Nucleotide) X-12844 (Unknown) |
| Biochemical locus-metabolite relationship | AKR1D1 encodes an NADPH-dependent delta 4-3-ketosteroid-5-beta-reductase, which catalyzes 5-beta-reduction of certain steroid molecules [7508385]. X-12095 was identified as N1-methyl-3-pyridone-4-carboxamide, an endproduct of NAD degradation. Ratio interpretation: n/a. |
| eQTL associations | - |
| Medical information | |
|---|---|
| Complex trait associations | - |
| Known metabolite associations | - |
| Inborn error of metabolism | Congenital bile acid synthesis defect type 2 |
| Pharmacological information | |
|---|---|
| ChEMBL ID | - |
| Drug information | Azelaic acid seems to inhibit this protein (PMID: 3207614) |
| Locus information for top associated metabolite | |
|---|---|
HapMap2 imputation![]() | 1KGP imputation![]() |








